Palvella Therapeutics (PVLA) 10-K 29 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 08, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001583648
Entity Registrant Name	PIERIS PHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-37471
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	30-0784346
Entity Address, Address Line One	225 Franklin Street, 26th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	857
Local Phone Number	246-8998
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PIRS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 11,222,444
Entity Common Stock, Shares Outstanding		98,935,025
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Boston, Massachusetts

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,396	$ 38,635
Short term investments	8,970	20,534
Accounts receivable	572	5,810
Receivable from public grants	3,141	4,771
Other receivables	2,326	462
Assets held for sale, property and equipment	2,188	0
Prepaid expenses and other current assets	4,087	3,212
Total current assets	38,680	73,424
Property and equipment, net	0	16,992
Operating lease right-of-use assets, non-current	0	3,705
Other non-current assets	0	1,369
Total assets	38,680	95,490
Current liabilities:
Accounts payable	3,372	4,154
Operating lease liabilities, current	0	859
Accrued expenses and other current liabilities	8,550	10,746
Deferred revenues, current portion	0	20,824
Total current liabilities	11,922	36,583
Deferred revenue, net of current portion	0	18,734
Operating lease liabilities, non-current	0	12,244
Total liabilities	11,922	67,561
Commitments and Contingencies
Stockholders’ equity:
Convertible preferred stock, $0.001 par value per share, 10,000,000 shares authorized and 15,617 shares issued and outstanding at December 21, 2023 and 2022	0	0
Common stock, $0.001 par value per share, 300,000,000 shares authorized and 98,935,025 and 74,519,103 shares issued and outstanding at December 21, 2023 and 2022, respectively	98	74
Additional paid-in capital	341,596	318,530
Accumulated other comprehensive income	28	(254)
Accumulated deficit	(314,964)	(290,421)
Total stockholders’ equity	26,758	27,929
Total liabilities and stockholders’ equity	$ 38,680	$ 95,490

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)	10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)	15,617	15,617
Preferred Stock, Shares Outstanding (in shares)	15,617	15,617
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized (in shares)	300,000,000	300,000,000
Common Stock, Shares Issued (in shares)	98,935,025	74,519,103
Common Stock, Shares Outstanding (in shares)	98,935,025	74,519,103

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue
Customer revenue	$ 38,711	$ 25,469
Collaboration revenue	4,099	433
Total revenue	42,810	25,902
Operating expenses
Research and development	41,801	52,982
General and administrative	16,853	16,394
Asset impairment	13,912	0
Total operating expenses	72,566	69,376
Loss from operations	(29,756)	(43,474)
Other income (expense)
Interest income	1,851	721
Grant income	3,612	8,173
Other (expense) income	(250)	1,303
Net loss	(24,543)	(33,277)
Other comprehensive (loss) income:
Foreign currency translation	208	(1,010)
Unrealized gain (loss) on available-for-sale securities	74	(73)
Comprehensive loss	$ (24,261)	$ (34,360)
Net loss per share
Basic and diluted (in dollars per share)	$ (0.27)	$ (0.45)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	90,064	74,172

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	At the Market Offering [Member] Preferred Stock [Member]	At the Market Offering [Member] Common Stock [Member]	At the Market Offering [Member] Additional Paid-in Capital [Member]	At the Market Offering [Member] AOCI Attributable to Parent [Member]	At the Market Offering [Member] Retained Earnings [Member]	At the Market Offering [Member]	Private Placement [Member] Preferred Stock [Member]	Private Placement [Member] Common Stock [Member]	Private Placement [Member] Additional Paid-in Capital [Member]	Private Placement [Member] AOCI Attributable to Parent [Member]	Private Placement [Member] Retained Earnings [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021													16,000	72,222,000
Balance at Dec. 31, 2021													$ 0	$ 72	$ 306,998	$ 829	$ (257,144)	$ 50,755
Net loss													0	0	0	0	(33,277)	(33,277)
Foreign currency translation adjustment													0	0	0	(1,010)	0	(1,010)
Unrealized loss on investments													0	0	0	(73)	0	(73)
Stock based compensation expense													$ 0	$ 0	4,402	0	0	4,402
Issuance of common stock resulting from exercise of stock options (in shares)													0	46,000
Issuance of common stock resulting from exercise of stock options													$ 0	$ 0	95	0	0	$ 95
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)													0	182,000				181,466
Issuance of common stock resulting from purchase of employee stock purchase plan shares													$ 0	$ 0	197	0	0	$ 197
Issuance of common stock (in shares)	0	2,069,000
Issuance of common stock	$ 0	$ 2	$ 6,838	$ 0	$ 0	$ 6,840
Balance (in shares) at Dec. 31, 2022							16,000	74,519,000
Balance at Dec. 31, 2022							$ 0	$ 74	$ 318,530	$ (254)	$ (290,421)	$ 27,929						27,929
Net loss													0	0	0	0	(24,543)	(24,543)
Foreign currency translation adjustment													0	0	0	208	0	208
Unrealized loss on investments													0	0	0	74	0	74
Stock based compensation expense													$ 0	$ 0	3,349	0	0	$ 3,349
Issuance of common stock resulting from purchase of employee stock purchase plan shares (in shares)													0	155,000				154,656
Issuance of common stock resulting from purchase of employee stock purchase plan shares													$ 0	$ 0	66	0	0	$ 66
Issuance of common stock (in shares)													0	24,261,000
Issuance of common stock													$ 0	$ 24	19,651	0	0	19,675
Balance (in shares) at Dec. 31, 2023													16,000	98,935,000
Balance at Dec. 31, 2023													$ 0	$ 98	$ 341,596	$ 28	$ (314,964)	$ 26,758

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parentheticals) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
At the Market Offering [Member]
Stock issuance costs		$ 0.3
Stock issuance costs	$ 0.7

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (24,543)	$ (33,277)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization (accretion)	1,904	2,770
Right-of-use asset (accretion) amortization	(123)	10
Stock-based compensation	3,349	4,402
Asset impairment	13,912	0
Realized investment gains	(53)	(376)
Other non-cash transactions	(124)	(91)
Accounts receivable	5,307	(2,624)
Prepaid expenses and other assets	1,018	(1,358)
Deferred revenue	(39,967)	(20,185)
Account payable	(789)	(4,208)
Accrued expenses and other liabilities	(2,336)	(4,005)
Lease liability, prior to operating lease termination	(868)	(990)
Change in lease liability due to termination of operating lease	(10,506)	0
Net cash used in operating activities	(53,819)	(59,932)
Investing activities:
Purchases of property and equipment	(171)	(1,041)
Proceeds from maturity of investments	35,008	28,200
Purchases of investments	(22,835)	(48,395)
Net cash provided by (used in) investing activities	12,002	(21,236)
Financing activities:
Proceeds from exercise of stock options	0	95
Proceeds from employee stock purchase plan	66	197
Proceeds from issuance of common stock resulting from ATM sales, net of $0.7 million and $0.3 million in transaction costs, respectively	19,729	6,922
Net cash provided by financing activities	19,795	7,214
Effect of exchange rate change on cash and cash equivalents	783	(5,175)
Net decrease in cash and cash equivalents	(21,239)	(79,129)
Cash and cash equivalents at beginning of period	38,635	117,764
Cash and cash equivalents at end of period	17,396	38,635
Supplemental cash flow disclosures:
Net unrealized gain (loss) on investments	74	(73)
Property and equipment included in accounts payable	$ 0	$ 193

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
At the Market Offering [Member] | Common Stock [Member]
Stock issuance costs	$ 0.7

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. OTHER INFORMATION Not
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Corporate Information

Note 1 - Corporate Information	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Corporate Information Pieris Pharmaceuticals, Inc., or the Company or Pieris, was founded in May 2013, 2001 December 2014. July 2023, The Company’s core Anticalin technology and platform was developed in Germany. On July 18, 2023 , one 2a 4Rα Also on July 18, 2023 , July 2023, December 31, 2023, 2023 2024. On March 27, 2024, 2027, 4 1BB may first 2 BB228, S095012 344 342, 1 first BB228, S095012 342. 2024, second 2024, second 2024. may may As of December 31, 2023 December 31, 2023 2022 December 31, 2023 The Company has historically devoted substantially all of its financial resources and efforts to research and development and general and administrative expenses to support the discovery and development of Anticalin-based drugs. Going forward, as part of the Company's decision to implement measures to maximize its ability to capture potential milestones from its partnered programs with Pfizer, Boston Pharmaceuticals, and Servier, the Company plans to discontinue all research and development efforts and reduce discretionary expenditures and other fixed or variable personnel costs. The Company believes that its currently available funds will be sufficient to fund its operations through at least the next twelve 10 may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated. The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris’ foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders’ equity. Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 830, Foreign Currency Matters. Cash, Cash Equivalents and Investments The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of 90 320, Investments Debt and Equity Securities Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company’s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense). The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no not not not Fair Value Measurement The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures 820, not one three • Level 1 • Level 2 not • Level 3 To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any ( Note 5 An entity may not Fair Values of Financial Instruments The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent third Accounts Receivable Accounts receivable are recorded net of allowances for credit losses and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for credit losses is necessary. The Company determined that no December 31, 2023 2022 not Property and Equipment Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows: Asset Classification Estimated useful life (in years) Leasehold improvements shorter of useful life or remaining life of the lease Laboratory furniture and equipment 8-14 Office furniture and equipment 5-13 Computer and equipment 3 - 7 If the criteria in ASC 360 Property, Plant and Equipment not no Impairment of Long-lived Assets The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not Revenue Recognition Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which may may no Collaborative Arrangements The Company considers the nature and contractual terms of an arrangement and assesses whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC 808, Collaborative Arrangements 808, not Revenue from Contracts with Customers In accordance with ASC 606, five 1 2 3 4 5 The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered not Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract may not If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one may one When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue. Milestones and Royalties The Company aggregates milestones into four first There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration. The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation. Contract Balances The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has not In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled. Costs to Obtain and Fulfill a Contract with a Customer Certain costs to obtain customer contracts, including success-based fees paid to third 340, Other Assets and Deferred Costs 340. Research and Development Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred. Income Taxes The Company applies ASC Topic 740 Income Taxes not not The Tax Cuts and Jobs Act (TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. Stock-based Compensation The Company measures share-based payments in accordance with ASC Topic 718, Stock Compensation The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option’s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid dividends, but may All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended December 31, 2023 2022 not Government Grants The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations. Leases The Company accounts for leases pursuant to ASC 842 Leases (Topic 842 842. The Company determines if an arrangement is a lease at inception. The Company’s contracts are determined to contain a lease within the scope of ASC 842 1 no 2 3 not 12 not not At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreements do not may The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are not not Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not When a lease is terminated in its entirety, the corresponding lease liability and right-of-use asset are adjusted to zero. Any difference between the carrying amounts of the right-of-use asset and lease liability as compared to the termination payment is recorded in the statement of operations as a gain or loss. Contingencies Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements. Segment Reporting Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer. Earnings per Share Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented. Recent Accounting Pronouncements Not The Company has considered recent accounting pronouncements and concluded that they are either not not

Note 3 - Revenue

Note 3 - Revenue	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue General The Company has not During the years ended December 31, 2023 2022 Year Ended December 31, 2023 2022 AstraZeneca $ 8,399 $ 9,117 Pfizer 15,134 8,287 Servier 4,099 5,359 Genentech 12,697 3,139 Boston Pharmaceuticals 2,481 — Total Revenue $ 42,810 $ 25,902 Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions) as of December 31, 2023 Research, Development, Regulatory & Commercial Milestones Sales Milestones Pfizer $ 759 $ 450 Servier 107 99 Boston Pharmaceuticals 85 265 Total potential milestone payments $ 951 $ 814 Strategic Partnerships Genentech On May 19, 2021, may Under the terms of the Genentech Agreement, the Company was responsible for discovery and preclinical development of two April May 2023 , $12.5 second 2023 . The Genentech Agreement also provided an option to select additional programs, at Genentech's discretion, for a fee and this option expires in May 2024. two December 31, 2023 Boston Pharmaceuticals On April 24, 2021, 342, 4 1BB/GPC3 Under the terms of the BP Agreement, Boston Pharmaceuticals exclusively licensed worldwide rights to PRS- 342. 342 The Company completed all performance obligations in 2021, August 2023, first 1/2 342 Pfizer  On February 8, 2018, Under the terms of the Pfizer Agreements, the companies pursued multiple Anticalin-antibody fusion proteins during the research phase. The Pfizer Agreements provide Pfizer a base option to select up to three programs for further development. Prior to the initiation of a pivotal trial, the Company may second may On March 24, 2021, one one 4 2 1933, may 606 F- 18 In the second 2022, second Under the Pfizer Agreements, the Company is eligible to receive various research, development, commercial and sales milestones. There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not In January 2023, first 606 no December 31, 2022 December 31, 2022. In September 2023 , no September 2023 December 2023, two December 31, 2023 AstraZeneca On May 2, 2017, June 10, 2017, 1976. In addition to the Company’s former lead inhaled drug candidate, PRS- 060/AZD1402, June 2023, three first 2022, third second 2023. third June 30, 2023, no The Company was responsible for advancing the AstraZeneca Lead Product through its phase 1 2a 2a two four two On July 17, 2023, October 15, 2023. 13 fourth September 30, 2023. no not The Company incurred $1.6 million of third 606, 340. December 31, 2022 Servier In 2017, In the first 2022, S095025 352 , fourth 2022, S095025 not four In July 2023, S095012 344 4 1BB/PD L1 S095012 344 S095012 344 S095012 344 2023 no Contract Balances The Company receives payments from its collaboration partners based on payments established in each contract. Upfront payments and fees are recorded as deferred revenue upon receipt or when due until such time as the Company satisfies its performance obligations under each arrangement. A contract asset is a conditional right to consideration in exchange for goods or services that the Company has transferred to a customer. Amounts are recorded as accounts receivable when the Company’s right is unconditional. There were no additions to deferred revenue during the year ended December 31, 2023 December 31, 2023

Note 4 - Grant Income

Note 4 - Grant Income	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Government Assistance [Text Block]	4. Grant Income One of the Company's proprietary respiratory assets is PRS- 220, June 2021, €14.2 2 19 The Bavarian Grant provides partial reimbursement for qualifying research and development activities on PRS- 220, 1 December 2023, February 2024, may In addition, the Company is required to communicate if there is a change in control or other event that would impact the continuation of PRS- 220 may

Note 5 - Cash, Cash Equivalents

Note 5 - Cash, Cash Equivalents and Investments	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Cash, Cash Equivalents, and Marketable Securities [Text Block]	5. Cash, Cash Equivalents and Investments As of December 31, 2023 December 31, 2022 2 December 31, 2023 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2023 Money market funds, included in cash equivalents $ 13,224 $ 13,224 $ — $ — Investments - US treasuries 8,970 8,970 — — Total $ 22,194 $ 22,194 $ — $ — Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2022 Money market funds, included in cash equivalents $ 17,618 $ 17,618 $ — $ — Investments - US treasuries 3,573 3,573 — — Investments - Foreign treasuries 896 896 — — Investments - Asset-backed securities 499 — 499 — Investments - Corporate bonds 15,566 — 15,566 — Total $ 38,152 $ 22,087 $ 16,065 $ — Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third third not December 31, 2023 Investments at December 31, 2023 Contractual maturity (in days) Amortized Cost Unrealized gains Unrealized losses Fair Value Investments US treasuries 4-51 $ 8,969 $ 1 $ — $ 8,970 Total $ 8,969 $ 1 $ — $ 8,970 The Company recorded realized losses from the maturity of available-for-sale securities of $0.1 million and realized gains of $0.4 million for the years ended December 31, 2023 2022, As of December 31, 2023 no

Note 6 - Assets Held for Sale,

Note 6 - Assets Held for Sale, Property and Equipment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Assets Held for Sale and Property, Plant and Equipment Disclosure [Text Block]	6. Assets Held for Sale, Property and Equipment As of December 31, 2023 December 31, 2023 Laboratory furniture and equipment $ 1,967 Office furniture and equipment 221 Assets held for sale $ 2,188 At the end of the third 2023, The Company recorded impairment charges totaling $13.9 million, of which $1.8 million related to impairment of its right-of-use asset under the Hallbergmoos Lease (see Note 13 3 first 2024, third second 2024. As of December 31, 2022 December 31, 2022 Laboratory furniture and equipment $ 11,970 Office furniture and equipment 1,861 Computer equipment 364 Leasehold improvements 12,444 Property and equipment, cost 26,639 Accumulated depreciation (9,647 ) Property and equipment, net $ 16,992 Depreciation expense was $1.8 million and $2.3 million for the years ended December 31, 2023 2022 no

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued Expenses Accrued expenses and other current liabilities consisted of the following (in thousands): Years Ended December 31, 2023 2022 Compensation expense $ 6,448 $ 3,015 Research and development fees 968 5,758 Accrued accounts payable 558 1,245 Other current liabilities 363 483 Accrued license obligations 213 245 Total $ 8,550 $ 10,746 The compensation expense line item in the above table includes both severance and benefit costs associated with the Company's corporate restructuring actions announced in 2023, one 2024. The following table includes a roll forward of the restructuring activity and payments recorded for the year ended December 31, 2023 ( Severance and Benefits Costs Restructuring expenses $ 7,523 Cash payments $ (2,418 ) Balance at December 31, 2023 $ 5,105

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. Income Taxes The Company reported a loss before income taxes consisting of the following (in thousands): Years Ended December 31, 2023 2022 Domestic $ (9,818 ) $ (11,765 ) Foreign (14,726 ) (21,512 ) Loss before income taxes $ (24,544 ) $ (33,277 ) The components of the provision for income taxes are as follows (in thousands): Years Ended December 31, 2023 2022 Current: Federal $ — $ — State — — Foreign — — Total current — — Deferred: Federal — — State — — Foreign — — Total deferred — — Provision for income taxes $ — $ — The reconciliation of the federal statutory rate to the Company’s effective tax rate is as follows: 2023 2022 Federal income tax rate 21.0 % 21.0 % Foreign rate differential 0.7 % 5.0 % State tax, net of federal benefit 3.8 % 2.0 % Share-based awards compensation (2.1 )% (2.2 )% Permanent items (2.1 )% 0.3 % Other (1.0 )% 1.0 % Release of uncertain tax position 22.7 % — % Credits 0.8 % 1.2 % Change in valuation allowance (43.8 )% (28.3 )% Effective income tax rate — % — % The components of deferred tax assets and liabilities related to net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income taxes purposes were as follows (in thousands): Years Ended December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 67,496 $ 54,845 Share-based awards compensation 2,624 3,112 Accrued expenses 461 216 R&D Credits 644 413 Depreciation and other 479 384 Unrealized foreign currency (377 ) 359 Capitalized R&D 1,165 952 Lease liability — 3,541 Total deferred tax assets 72,492 63,822 Deferred tax liabilities: Right-of-use asset — (3,270 ) Accrued expenses — — Total deferred tax liabilities — (3,270 ) Less: valuation allowance: (72,492 ) (60,552 ) Net deferred tax asset $ — $ — The Company operates in multiple jurisdictions. Accordingly, the Company files U.S. federal and state income tax returns as well as returns in multiple foreign jurisdictions. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not not not not December 31, 2023 The cumulative amount of earnings of our foreign subsidiaries are expected to be permanently invested in the foreign subsidiaries. Deferred taxes have not not The increase in the valuation allowance of deferred tax assets of $11.9 million for the year ended December 31, 2023 As of December 31, 2023 December 31, 2017 2037 not 2035. 382 1986, may may may 382 may 382 December 31, 2020. 382 February 2018. 382; not February 2018 not 382, may 2019 may not As of December 31, 2023 may $1.2 60% not may may As of December 31, 2023, may 2042 2037, December 31, 2022, may 2042 2037, The Company accounts for uncertain tax positions pursuant to ASC 740, Income Taxes not December 31, 2023 December 31, 2022 On December 22, 2017, January 1, 2022, no five 15 The following table sets forth a reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding the impact of interest and penalties, for the year ended December 31, 2023 Unrecognized tax benefits at December 31, 2022 $ 5,363 Decrease as a result of a lapse of the applicable statute of limitations (5,363 ) Unrecognized tax benefits at December 31, 2023 $ — The Company does not twelve

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	9. Stockholders equity The Company had 300,000,000 shares authorized and 98,935,025 and 74,519,103 shares of common stock issued and outstanding as of December 31, 2023 December 31, 2022 The Company had 10,000,000 shares authorized and 15,617 shares of preferred stock issued and outstanding as of December 31, 2023 2022 • Series A Convertible, 85 shares issued and outstanding at December 31, 2023 2022 • Series B Convertible, 4,026 shares issued and outstanding at December 31, 2023 2022 • Series C Convertible, 3,506 shares issued and outstanding at December 31, 2023 2022 • Series D Convertible, 3,000 shares issued and outstanding at December 31, 2023 2022 • Series E Convertible, 5,000 shares issued and outstanding at December 31, 2023 2022 Common Stock Each share of the Company’s common stock is entitled to one vote and all shares rank equally as to voting and other matters. Dividends may Preferred Stock The Company has issued multiple series (Series A through E) of preferred stock to certain entities affiliated with Biotechnology Value Fund, L.P., or BVF. In each case, each share Preferred Stock is convertible into 1,000 shares of the Company's common stock (subject to adjustment as provided in the Certificate of Designation for each series) at any time at the option of the holder, provided that the holder is prohibited from converting the Preferred Stock into shares of the Company's common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of Common Stock then issued and outstanding, or the Beneficial Ownership Limitation. The holder may not Series A, Series B, Series C, Series D and Series E Preferred Stock rank senior to the Company’s common stock; senior to any class or series of capital stock of the Company created after the designation of and specifically ranking by its terms as junior to the five five five five For each series of Preferred Stock, the Company designated the requisite number of shares of its authorized and unissued preferred stock as a specific series of Preferred Stock and filed a Certificate of Designation with the Nevada Secretary of State. Shares of Preferred Stock generally have no Series A Preferred Stock In June 2016, 2016 2016 2016 2016 Series B Preferred Stock On January 30, 2019, Series C and 2019 In November 2019, one one one If (i) the initial public disclosure of the phase 2a 2a 0.05 0.05 one 10 three 60 may five not Upon issuance, each Series C Preferred Share included an embedded beneficial conversion feature as the market price of the Company’s common stock on the date of issuance of the Series C convertible Preferred Stock was $3.43 per share. As a result, the Company recorded the intrinsic value of the beneficial conversion feature of $2.8 million as a discount on the Series C convertible preferred stock at issuance. As the Series C Preferred Shares are immediately convertible upon issuance and do not Series D Preferred Stock Conversion On March 31, 2020, April 1, 2020, Series E Preferred Stock Conversion On May 20, 2021, Open Market Sales Agreement In August 2021, may November 2022, may 3 August 2021. December 31, 2023 December 31, 2022 As of the filing of this Annual Report on Form 10 3 12 3 one third 3, $75

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	10. Net Loss per Share Basic net loss per share is calculated by dividing net income (loss) by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, preferred stock, stock options, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented. For the years ended December 31, 2023 2022

Note 11 - Stock and Employee Be

Note 11 - Stock and Employee Benefit Plans	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. Stock and Employee Benefit Plans Employee, Director and Consultant Equity Incentive Plans At the 2020 June 23, 2020, 2020 2020 2020 2020 2020 2019 2019 no 2019 2020 2020 2019 2021 June 25, 2021, first 2020 2020 2020 2022 June 22, 2022, second 2020 2020 2023 June 21, 2023, third 2020 2020 2020 2020 2020 may 2014, 2016, 2018 2019 The Company’s stock options have a maximum term of 10 years from the date of grant. Stock options granted may The Company estimates the fair value of each stock award on the grant date using the Black-Scholes option-pricing model based on the following assumptions: Years Ended December 31, 2023 2022 Risk free interest rate 3.33% - 4.11% 1.43% - 3.39% Expected term (in years) 5.5 - 5.73 5.5 - 5.73 Dividend yield — — Expected volatility 79.5% - 98.6% 79.9% - 81.1% The weighted-average fair value of the 3,727,942 and 3,075,282 options granted during the years ended December 31, 2023 2022 December 31, 2023 2020 The following table summarizes stock option activity for employees and non-employees: Weighted- Weighted- Average Aggregate Average Remaining Intrinsic Number of Exercise Contractual Value Options Price Life (in years) (in thousands) Outstanding, December 31, 2022 13,430,366 $ 3.21 $ — Granted 3,727,942 1.22 — Canceled/Forfeited 2,655,237 2.65 — Outstanding, December 31, 2023 14,503,071 $ 2.80 5.90 $ — Vested or expected to vest, December 31, 2023 14,503,071 $ 2.80 5.90 $ — Exercisable, December 31, 2023 10,292,063 $ 3.21 4.75 $ — Periodically, the Company grants inducement options, which are awards outside of stockholder-approved stock option plans, and which are awarded as an inducement material to the executive officers or other personnel entering senior leadership roles with the Company. The terms of inducement option awards were substantially the same as those issued under our 2020 Weighted- Weighted- Average Aggregate Average Remaining Intrinsic Number of Exercise Contractual Value Options Price Life (in years) (in thousands) Outstanding, December 31, 2022 300,000 $ 4.65 $ — Granted — $ — $ — Canceled/Forfeited — $ — $ — Outstanding, December 31, 2023 300,000 $ 4.65 5.67 $ — Vested or expected to vest, December 31, 2023 300,000 $ 4.65 5.67 $ — Exercisable, December 31, 2023 300,000 $ 4.65 5.67 $ — Employee Stock Purchase Plans At the 2023 2023 2023 2018 2018 2023 2023 Total shares purchased under the 2023 2018 December 31, 2023 2022 Total Stock-based Compensation Expense Total stock-based compensation expense is recorded in operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands): Years Ended December 31, 2023 2022 Research and development $ 1,190 $ 1,905 General and administrative 2,159 2,497 Total stock-based compensation $ 3,349 $ 4,402 As of December 31, 2023

Note 12 - License Agreement

Note 12 - License Agreement	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
License and Transfer Agreement [Text Block]	12. License Agreement TUM License The Company and the Technical University of Munich, or TUM, initiated discussions in the second 2018 not may may

Note 13 - Leases

Note 13 - Leases	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	13. Leases In August 2015, December 31, 2022. not In October 2018, February 2020. May 2019 February 2020. In December 2023, €9.7 December 31, 2023, June 2024, Cash paid for amounts included in the measurement of the lease liabilities were $2.2 million and $2.4 million for the years ended December 31, 2023 2022 third 2023. The following table summarizes operating lease costs included in operating expenses (in thousands): Year Ended December 31, 2023 2022 Operating lease costs $ 1,169 $ 1,356 Variable lease costs (1) 679 737 Total lease cost $ 1,848 $ 2,093 ( 1

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Use of Estimates The accompanying consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated. The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The financial statements of the Company’s foreign subsidiaries are translated from local currency into reporting currency, which is U.S. dollars, using the current exchange rate at the balance sheet date for assets and liabilities, and the weighted average exchange rate prevailing during the period for revenues and expenses. The functional currency for Pieris’ foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders’ equity. Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as other (expense) income, net in the consolidated statements of operations. Foreign currency gains and losses on available-for-sale investment transactions are recorded to other comprehensive income (loss) on the Company's balance sheet per Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 830, Foreign Currency Matters.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Investments The Company determines the appropriate classification of its investments at the time of purchase. All liquid investments with original maturities of 90 320, Investments Debt and Equity Securities Available-for-sale investments are recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the Company’s balance sheets. Realized gains and losses are determined using the specific identification method and are included as a component of other income (expense). The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no not not not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurement The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC Topic 820, Fair Value Measurement and Disclosures 820, not one three • Level 1 • Level 2 not • Level 3 To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. Financial instruments measured at fair value on a recurring basis include cash equivalents and investments, if any ( Note 5 An entity may not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Values of Financial Instruments The fair value of cash, accounts receivable, and accounts payable approximates the carrying value of these financial instruments because of the short-term nature of any maturities. The Company determines the estimated fair values of other financial instruments, using available market information and valuation methodologies, primarily input from independent third
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded net of allowances for credit losses and represent amounts due from strategic partners. The Company monitors and evaluates collectability of receivables on an ongoing basis and considers whether an allowance for credit losses is necessary. The Company determined that no December 31, 2023 2022 not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at acquisition cost, less accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the remaining estimated useful lives of the assets. Maintenance and repairs to these assets are charged to expenses as occurred. Substantially all of the Company's fixed assets are located in Germany. The estimated useful life of the different groups of property and equipment is as follows: Asset Classification Estimated useful life (in years) Leasehold improvements shorter of useful life or remaining life of the lease Laboratory furniture and equipment 8-14 Office furniture and equipment 5-13 Computer and equipment 3 - 7 If the criteria in ASC 360 Property, Plant and Equipment not no
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-lived Assets The Company reviews its long-lived assets to be held and used for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Pieris has entered into several licensing agreements with collaboration partners for the development of Anticalin therapeutics against a variety of targets. The terms of these agreements provide for the transfer of multiple goods or services which may may no Collaborative Arrangements The Company considers the nature and contractual terms of an arrangement and assesses whether the arrangement involves a joint operating activity pursuant to which it is an active participant and exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and exposed to the significant risks and rewards with respect to the arrangement, it accounts for these arrangements pursuant to ASC 808, Collaborative Arrangements 808, not Revenue from Contracts with Customers In accordance with ASC 606, five 1 2 3 4 5 The Company evaluates all promised goods and services within a customer contract and determines which of such goods and services are separate performance obligations. This evaluation includes an assessment of whether the good or service is capable of being distinct and whether the good or service is separable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property and the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available. Licensing arrangements are analyzed to determine whether the promised goods or services, which often include licenses, research and development services and governance committee services, are distinct or whether they must be accounted for as part of a combined performance obligation. If the license is considered not Certain contracts contain optional and additional items, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. A contract may not If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price among the performance obligations on a relative standalone selling price basis unless a portion of the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct good or service that forms part of a single performance obligation. The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one may one When a performance obligation is satisfied, revenue is recognized for the amount of the transaction price, excluding estimates of variable consideration that are constrained, that is allocated to that performance obligation on a relative standalone selling price basis. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under an arrangement. For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non- refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. Revenue recognized under an arrangement involving a participant that is a customer is presented as Customer Revenue. Milestones and Royalties The Company aggregates milestones into four first There is uncertainty that the events to obtain the research and development milestones will be achieved given the nature of clinical development and the stage of the Company’s technology. The Company has thus determined that all research and development milestones will be constrained until it is deemed probable that a significant revenue reversal will not For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Commercial milestones and sales royalties are determined by sales or usage-based thresholds and will be accounted for under the royalty recognition constraint as constrained variable consideration. The Company calculates the maximum amount of potential milestones achievable under each collaboration agreement and discloses such potential future milestones for all current collaborations using such a maximum calculation. Contract Balances The Company recognizes a contract asset when the Company transfers goods or services to a customer before the customer pays consideration or before payment is due, excluding any amounts presented as a receivable (i.e., accounts receivable). A contract asset is an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer. The contract liabilities (i.e., deferred revenue) primarily relate to contracts where the Company has received payment but has not In the event of an early termination of a collaboration agreement, any contract liabilities would be recognized in the period in which all Company obligations under the agreement have been fulfilled. Costs to Obtain and Fulfill a Contract with a Customer Certain costs to obtain customer contracts, including success-based fees paid to third 340, Other Assets and Deferred Costs 340.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses are charged to the statement of operations as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, pre-clinical and clinical costs, contract services, consulting, depreciation and amortization expense, and other related costs. Costs associated with acquired technology, in the form of upfront fees or milestone payments, are charged to research and development expense as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company applies ASC Topic 740 Income Taxes not not The Tax Cuts and Jobs Act (TCJA) subjects a U.S. shareholder to tax on global-intangible low tax income (GILTI) earned by certain foreign subsidiaries. The Company has made an accounting policy election to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.
Share-Based Payment Arrangement [Policy Text Block]	Stock-based Compensation The Company measures share-based payments in accordance with ASC Topic 718, Stock Compensation The Company uses the Black-Scholes option pricing model to determine the estimated fair value for stock-based awards. Option-pricing models require the input of various subjective assumptions, including the option’s expected life, expected dividend yield, price volatility, risk free interest rate and forfeitures of the underlying stock. Due to the limited operating history of the Company as a public entity and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company computes historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Due to the lack of Company specific historical option activity, the Company has estimated the expected term of its employee stock options using the “simplified” method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term for non-employee awards is the remaining contractual term of the option. The risk-free interest rates are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company has never paid dividends, but may All excess tax benefits and tax deficiencies are recorded as income tax expense or benefit in the Company's statement of operations and comprehensive loss. For the years ended December 31, 2023 2022 not
Government Assistance [Policy Text Block]	Government Grants The Company recognizes grants from governmental agencies when there is reasonable assurance that the Company will comply with the conditions attached to the grant arrangement and the grant will be received. The Company evaluates the conditions of each grant as of each reporting period to evaluate whether the Company has reached reasonable assurance of meeting the conditions of each grant arrangement and that it is expected that the grant will be received as a result of meeting the necessary conditions. Grants are recognized in the consolidated statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate. Specifically, grant income related to research and development costs is recognized as such expenses are incurred. Grant income is included as a separate caption within Other income (expense), net in the consolidated statements of operations.
Lessee, Leases [Policy Text Block]	Leases The Company accounts for leases pursuant to ASC 842 Leases (Topic 842 842. The Company determines if an arrangement is a lease at inception. The Company’s contracts are determined to contain a lease within the scope of ASC 842 1 no 2 3 not 12 not not At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company’s lease agreements do not may The Company typically only includes an initial lease term in its assessment of a lease agreement. Options to renew a lease are not not Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not When a lease is terminated in its entirety, the corresponding lease liability and right-of-use asset are adjusted to zero. Any difference between the carrying amounts of the right-of-use asset and lease liability as compared to the termination payment is recorded in the statement of operations as a gain or loss.
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies Accruals are recorded for loss contingencies when it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. Considering facts known at the time of the assessment, the Company determines whether potential losses are considered reasonably possible or probable and whether they are estimable. Based upon this assessment, the Company carries out an evaluation of disclosure requirements and considers possible accruals in the financial statements.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are identified as components of an enterprise where separate discrete financial information is evaluated by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company operates as a single segment dedicated to the discovery and development of biotechnological applications and the Company’s chief operating decision maker, or CODM, makes decisions based on the Company as a whole. The Company has determined that its CODM is its Chief Executive Officer.
Earnings Per Share, Policy [Policy Text Block]	Earnings per Share Basic earnings per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted earnings per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders' calculation, preferred stock, stock options, unvested restricted stock, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Not The Company has considered recent accounting pronouncements and concluded that they are either not not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment, Estimated Useful Life [Table Text Block]	Asset Classification Estimated useful life (in years) Leasehold improvements shorter of useful life or remaining life of the lease Laboratory furniture and equipment 8-14 Office furniture and equipment 5-13 Computer and equipment 3 - 7

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2023 2022 AstraZeneca $ 8,399 $ 9,117 Pfizer 15,134 8,287 Servier 4,099 5,359 Genentech 12,697 3,139 Boston Pharmaceuticals 2,481 — Total Revenue $ 42,810 $ 25,902
Revenue From Contract With Customer, Milestone Payments [Table Text Block]	Research, Development, Regulatory & Commercial Milestones Sales Milestones Pfizer $ 759 $ 450 Servier 107 99 Boston Pharmaceuticals 85 265 Total potential milestone payments $ 951 $ 814

Note 5 - Cash, Cash Equivalen_2

Note 5 - Cash, Cash Equivalents and Investments (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2023 Money market funds, included in cash equivalents $ 13,224 $ 13,224 $ — $ — Investments - US treasuries 8,970 8,970 — — Total $ 22,194 $ 22,194 $ — $ — Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2022 Money market funds, included in cash equivalents $ 17,618 $ 17,618 $ — $ — Investments - US treasuries 3,573 3,573 — — Investments - Foreign treasuries 896 896 — — Investments - Asset-backed securities 499 — 499 — Investments - Corporate bonds 15,566 — 15,566 — Total $ 38,152 $ 22,087 $ 16,065 $ —
Debt Securities, Available-for-Sale [Table Text Block]	Contractual maturity (in days) Amortized Cost Unrealized gains Unrealized losses Fair Value Investments US treasuries 4-51 $ 8,969 $ 1 $ — $ 8,970 Total $ 8,969 $ 1 $ — $ 8,970

Note 6 - Assets Held for Sale_2

Note 6 - Assets Held for Sale, Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]	December 31, 2023 Laboratory furniture and equipment $ 1,967 Office furniture and equipment 221 Assets held for sale $ 2,188
Property, Plant and Equipment [Table Text Block]	December 31, 2022 Laboratory furniture and equipment $ 11,970 Office furniture and equipment 1,861 Computer equipment 364 Leasehold improvements 12,444 Property and equipment, cost 26,639 Accumulated depreciation (9,647 ) Property and equipment, net $ 16,992

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	Years Ended December 31, 2023 2022 Compensation expense $ 6,448 $ 3,015 Research and development fees 968 5,758 Accrued accounts payable 558 1,245 Other current liabilities 363 483 Accrued license obligations 213 245 Total $ 8,550 $ 10,746
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Severance and Benefits Costs Restructuring expenses $ 7,523 Cash payments $ (2,418 ) Balance at December 31, 2023 $ 5,105

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended December 31, 2023 2022 Domestic $ (9,818 ) $ (11,765 ) Foreign (14,726 ) (21,512 ) Loss before income taxes $ (24,544 ) $ (33,277 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years Ended December 31, 2023 2022 Current: Federal $ — $ — State — — Foreign — — Total current — — Deferred: Federal — — State — — Foreign — — Total deferred — — Provision for income taxes $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2023 2022 Federal income tax rate 21.0 % 21.0 % Foreign rate differential 0.7 % 5.0 % State tax, net of federal benefit 3.8 % 2.0 % Share-based awards compensation (2.1 )% (2.2 )% Permanent items (2.1 )% 0.3 % Other (1.0 )% 1.0 % Release of uncertain tax position 22.7 % — % Credits 0.8 % 1.2 % Change in valuation allowance (43.8 )% (28.3 )% Effective income tax rate — % — %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Years Ended December 31, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 67,496 $ 54,845 Share-based awards compensation 2,624 3,112 Accrued expenses 461 216 R&D Credits 644 413 Depreciation and other 479 384 Unrealized foreign currency (377 ) 359 Capitalized R&D 1,165 952 Lease liability — 3,541 Total deferred tax assets 72,492 63,822 Deferred tax liabilities: Right-of-use asset — (3,270 ) Accrued expenses — — Total deferred tax liabilities — (3,270 ) Less: valuation allowance: (72,492 ) (60,552 ) Net deferred tax asset $ — $ —
Summary of Income Tax Contingencies [Table Text Block]	Unrecognized tax benefits at December 31, 2022 $ 5,363 Decrease as a result of a lapse of the applicable statute of limitations (5,363 ) Unrecognized tax benefits at December 31, 2023 $ —

Note 11 - Stock and Employee _2

Note 11 - Stock and Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years Ended December 31, 2023 2022 Risk free interest rate 3.33% - 4.11% 1.43% - 3.39% Expected term (in years) 5.5 - 5.73 5.5 - 5.73 Dividend yield — — Expected volatility 79.5% - 98.6% 79.9% - 81.1%
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted- Weighted- Average Aggregate Average Remaining Intrinsic Number of Exercise Contractual Value Options Price Life (in years) (in thousands) Outstanding, December 31, 2022 13,430,366 $ 3.21 $ — Granted 3,727,942 1.22 — Canceled/Forfeited 2,655,237 2.65 — Outstanding, December 31, 2023 14,503,071 $ 2.80 5.90 $ — Vested or expected to vest, December 31, 2023 14,503,071 $ 2.80 5.90 $ — Exercisable, December 31, 2023 10,292,063 $ 3.21 4.75 $ — Weighted- Weighted- Average Aggregate Average Remaining Intrinsic Number of Exercise Contractual Value Options Price Life (in years) (in thousands) Outstanding, December 31, 2022 300,000 $ 4.65 $ — Granted — $ — $ — Canceled/Forfeited — $ — $ — Outstanding, December 31, 2023 300,000 $ 4.65 5.67 $ — Vested or expected to vest, December 31, 2023 300,000 $ 4.65 5.67 $ — Exercisable, December 31, 2023 300,000 $ 4.65 5.67 $ —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Years Ended December 31, 2023 2022 Research and development $ 1,190 $ 1,905 General and administrative 2,159 2,497 Total stock-based compensation $ 3,349 $ 4,402

Note 13 - Leases (Tables)

Note 13 - Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, 2023 2022 Operating lease costs $ 1,169 $ 1,356 Variable lease costs (1) 679 737 Total lease cost $ 1,848 $ 2,093

Note 1 - Corporate Information

Note 1 - Corporate Information (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 27, 2024	Jul. 18, 2023	May 31, 2013
Reduction in Workforce, Percentage				70%
Reduction in Workforce, Cost	$ 7,500
Cash, Cash Equivalents, and Short-Term Investments	26,400
Net Income (Loss) Attributable to Parent	(24,543)	$ (33,277)
Retained Earnings (Accumulated Deficit)	$ (314,964)	$ (290,421)
Subsequent Event [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Phase 2 Trials [Member]
Contracts Receivable, Claims and Uncertain Amounts			$ 20,000
Subsequent Event [Member] | B P Assets X I I Inc [Member] | License [Member] | Exclusive Product License Agreement [Member] | Pivotal Clinical Trials [Member]
Contracts Receivable, Claims and Uncertain Amounts			$ 55,000
Pieris Pharmaceuticals GmbH [Member]
Business Acquisition, Percentage of Voting Interests Acquired					100%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details)	Dec. 31, 2023
Laboratory Equipment [Member] | Minimum [Member]
Property and equipment, useful life (Year)	8 years
Laboratory Equipment [Member] | Maximum [Member]
Property and equipment, useful life (Year)	14 years
Office Equipment [Member] | Minimum [Member]
Property and equipment, useful life (Year)	5 years
Office Equipment [Member] | Maximum [Member]
Property and equipment, useful life (Year)	13 years
Computer Equipment [Member] | Minimum [Member]
Property and equipment, useful life (Year)	3 years
Computer Equipment [Member] | Maximum [Member]
Property and equipment, useful life (Year)	7 years

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Apr. 24, 2021 USD ($)

Mar. 24, 2021 USD ($) $ / shares shares

Jan. 01, 2019 USD ($)

Sep. 30, 2023 USD ($)

Jan. 31, 2023 USD ($)

Jun. 30, 2023 USD ($)

Mar. 31, 2022 USD ($)

Sep. 30, 2023 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2017

May 19, 2021 USD ($)

Feb. 08, 2018

May 02, 2017 USD ($)

Contract with Customer, Liability, Current

$ 0

$ 20,824

Increase in Contract With Customer Liability

0

Decrease in Contract with Customer, Liability

39,700

Amendment of the Second Seagen Amendment [Member]

Revenue from Contract with Customer, Excluding Assessed Tax

$ 10,100

Genentech [Member]

Number Of Initial Research Programs

2

Contract with Customer, Liability, Revenue Recognized

$ 12,500

Seattle Genetics Inc. [Member]

Amended Collaboration Agreement, Resale of Stock, Period (Day)

60 days

Seattle Genetics Inc. [Member] | Private Placement [Member]

Contract with Customer, Liability, Total

$ 3,300

Sale of Stock, Number of Shares Issued in Transaction (in shares) | shares

3,706,174

Sale of Stock, Consideration Received on Transaction

$ 13,000

Sale of Stock, Price Per Share (in dollars per share) | $ / shares

$ 3.51

Sale of Stock, Fair Value, Price Per Share (in dollars per share) | $ / shares

$ 2.61

Seattle Genetics Inc. [Member] | License and Collaboration Agreement [Member]

Number of Research Programs

3

3

Seattle Genetics Inc. [Member] | Other Arrangement [Member]

Number of Research Programs

2

Seattle Genetics Inc. [Member] | Collaborative Arrangement [Member]

Revenue from Contract with Customer, Excluding Assessed Tax

$ 5,000

1,500

5,000

Astra Zeneca A B [Member]

Capitalized Contract Cost, Amortization

$ 300

Astra Zeneca A B [Member] | Accounting Standards Update 2014-09 [Member]

Capitalized Contract Cost, Net, Total

$ 1,600

Capitalized Contract Cost, Gross

$ 1,100

Capitalized Contract Cost, Amortization

$ 300

Astra Zeneca A B [Member] | License and Collaboration Agreement [Member]

Contract with Customer, Liability, Revenue Recognized

$ 4,000

$ 9,700

Contract with Customer, Liability, Current

$ 3,500

$ 3,500

Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Maximum [Member]

Number of Collaboration Products

4

Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Minimum [Member]

Number of Collaboration Products

2

Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]

Contract with Customer, Liability, Revenue Recognized

$ 4,900

Number of Programs

4

Number of Novel Proteins

1

Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | License and Collaboration Agreement [Member]

Contract with Customer, Liability, Current

$ 4,700

Number of Programs

5

License [Member] | Genentech [Member]

Contract with Customer, Liability, Total

$ 20,000

License [Member] | B P Assets X I I Inc [Member] | Exclusive Product License Agreement [Member]

Contract with Customer, Liability, Total

$ 10,000

Revenue from Contract with Customer, Contribution Towards Manufacturing Activities

$ 4,000

Note 3 - Revenue - Disaggregati

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 42,810	$ 25,902
Astra Zeneca A B [Member]
Total revenue	8,399	9,117
Pfizer [Member]
Total revenue	15,134	8,287
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Total revenue	4,099	5,359
Genentech [Member]
Total revenue	12,697	3,139
Boston Pharmaceuticals [Member]
Total revenue	$ 2,481	$ 0

Note 3 - Revenue - Potential Mi

Note 3 - Revenue - Potential Milestone Payments Received (Details) - Collaborative Arrangement [Member] - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Research And Development Milestone Payments [Member]
milestone	$ 951
Research And Development Milestone Payments [Member] | Pfizer [Member]
milestone	759
Research And Development Milestone Payments [Member] | Servier Developed Collaboration Products [Member]
milestone	107
Research And Development Milestone Payments [Member] | Boston Pharmaceuticals [Member]
milestone	$ 85
Sales Milestone Payments [Member]
milestone		$ 814
Sales Milestone Payments [Member] | Pfizer [Member]
milestone		450
Sales Milestone Payments [Member] | Servier Developed Collaboration Products [Member]
milestone		99
Sales Milestone Payments [Member] | Boston Pharmaceuticals [Member]
milestone		$ 265

Note 4 - Grant Income (Details

Note 4 - Grant Income (Details Textual) - Jun. 30, 2021 € in Millions, $ in Millions	USD ($)	EUR (€)
Grants Receivable	$ 17	€ 14.2

Note 5 - Cash, Cash Equivalen_3

Note 5 - Cash, Cash Equivalents and Investments (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-Sale, Realized Gain (Loss)	$ (0.1)	$ 0.4

Note 5 - Cash, Cash Equivalen_4

Note 5 - Cash, Cash Equivalents and Investments - Cash Equivalents and Investments Carried at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Fair Value	$ 8,970
Total	22,194	$ 38,152
Fair Value, Inputs, Level 1 [Member]
Total	22,194	22,087
Fair Value, Inputs, Level 2 [Member]
Total	0	16,065
Fair Value, Inputs, Level 3 [Member]
Total	0	0
Money Market Funds [Member]
Money market funds, included in cash equivalents	13,224	17,618
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market funds, included in cash equivalents	13,224	17,618
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market funds, included in cash equivalents	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market funds, included in cash equivalents	0	0
US Treasury Securities [Member]
Fair Value	8,970	3,573
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value	8,970	3,573
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value	0	0
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value	$ 0	0
Debt Security, Government, Non-US [Member]
Fair Value		896
Debt Security, Government, Non-US [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value		896
Debt Security, Government, Non-US [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value		0
Debt Security, Government, Non-US [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value		0
Asset-Backed Securities [Member]
Fair Value		499
Asset-Backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value		0
Asset-Backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value		499
Asset-Backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value		0
Corporate Bond Securities [Member]
Fair Value		15,566
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value		0
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value		15,566
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value		$ 0

Note 5 - Cash, Cash Equivalen_5

Note 5 - Cash, Cash Equivalents and Investments - Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Amortized cost	$ 8,969
Unrealized gains	1
Unrealized losses	0
Fair Value	8,970
US Treasury Securities [Member]
Amortized cost	8,969
Unrealized gains	1
Unrealized losses	0
Fair Value	$ 8,970	$ 3,573
US Treasury Securities [Member] | Minimum [Member]
Contractual Maturity Period (Day)	4 days
US Treasury Securities [Member] | Maximum [Member]
Contractual Maturity Period (Day)	51 days

Note 6 - Assets Held for Sale_3

Note 6 - Assets Held for Sale, Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Asset Impairment Charges	$ 13,912	$ 0
Long-Lived Assets Held-for-Sale, Net Book Value	2,188
Depreciation	1,800	$ 2,300
Office and Laboratory Space [Member] | Hallbergmoos Germany [Member]
Operating Lease, Impairment Loss	$ 1,800

Note 6 - Assets Held for Sale_4

Note 6 - Assets Held for Sale, Property and Equipment - Summary of Assets Held for Sale (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Net Book Value	$ 2,188
Laboratory Furniture and Equipment [Member]
Net Book Value	1,967
Office Furniture and Equipment [Member]
Net Book Value	$ 221

Note 6 - Assets Held for Sale_5

Note 6 - Assets Held for Sale, Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property and equipment, cost		$ 26,639
Accumulated depreciation		(9,647)
Property and equipment, net	$ 0	16,992
Laboratory Equipment [Member]
Property and equipment, cost		11,970
Office Equipment [Member]
Property and equipment, cost		1,861
Computer Equipment [Member]
Property and equipment, cost		364
Leasehold Improvements [Member]
Property and equipment, cost		$ 12,444

Note 7 - Accrued Expenses - Acc

Note 7 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Compensation expense	$ 6,448	$ 3,015
Research and development fees	968	5,758
Accrued accounts payable	558	1,245
Other current liabilities	363	483
Accrued license obligations	213	245
Total	$ 8,550	$ 10,746

Note 7 - Accrued Expenses - Res

Note 7 - Accrued Expenses - Restructuring Activity (Details) - Severance and Benefits Costs [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Restructuring expenses	$ 7,523
Cash payments	(2,418)
Balance at December 31, 2023	$ 5,105

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 11,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	0	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards	43,400
Domestic Tax Authority [Member] | Research and Development Tax [Member
Tax Credit Carryforward, Amount	$ 500	300
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Open Tax Year	2019 2020 2021 2022 2023
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 46,700
State and Local Jurisdiction [Member] | Research and Development Tax [Member
Tax Credit Carryforward, Amount	100	$ 100
Foreign Tax Authority [Member] | Corporate Income Tax [Member]
Operating Loss Carryforwards	187,600
Foreign Tax Authority [Member] | Trade Tax [Member]
Operating Loss Carryforwards	$ 183,700

Note 8 - Income Taxes - Schedul

Note 8 - Income Taxes - Schedule of Income Before Income Tax Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Domestic	$ (9,818)	$ (11,765)
Foreign	(14,726)	(21,512)
Loss before income taxes	$ (24,544)	$ (33,277)

Note 8 - Income Taxes - Sched_2

Note 8 - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal	$ 0	$ 0
State	0	0
Foreign, tax expense	0	0
Total current	0	0
Federal, deferred	0	0
State, deferred	0	0
Foreign, deferred	0	0
Total deferred	0	0
Provision for income taxes	$ 0	$ 0

Note 8 - Income Taxes - Sched_3

Note 8 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal income tax rate	21%	21%
Foreign rate differential	0.70%	5%
State tax, net of federal benefit	3.80%	2%
Share-based awards compensation, tax rate	(2.10%)	(2.20%)
Permanent items	(2.10%)	0.30%
Other	(1.00%)	1%
Release of uncertain tax position	22.70%	0%
Credits	0.80%	1.20%
Change in valuation allowance	(43.80%)	(28.30%)
Effective income tax rate	0%	0%

Note 8 - Income Tax - Schedule

Note 8 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Net operating loss carryforwards	$ 67,496	$ 54,845
Share-based awards compensation, tax assets	2,624	3,112
Accrued expenses, tax assets	461	216
R&D Credits	644	413
Depreciation and other	479	384
Unrealized foreign currency	(377)	(359)
Unrealized foreign currency	377	359
Capitalized R&D	1,165	952
Lease liability	0	3,541
Total deferred tax assets	72,492	63,822
Right-of-use asset	0	(3,270)
Total deferred tax liabilities	0	(3,270)
Less: valuation allowance:	(72,492)	(60,552)
Net deferred tax asset	$ 0	$ 0

Note 8 - Income Taxes - Summary

Note 8 - Income Taxes - Summary of Income Tax Contingencies (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Unrecognized tax benefits at December 31, 2022	$ 5,363
Decrease as a result of a lapse of the applicable statute of limitations	(5,363)
Unrecognized tax benefits at December 31, 2023	$ 0

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Millions								1 Months Ended			12 Months Ended
	Jun. 20, 2023 shares	Jun. 22, 2022 shares	Jun. 25, 2021 shares	May 20, 2021 $ / shares shares	Apr. 01, 2020 shares	Jan. 30, 2019 shares	Jun. 01, 2016 USD ($) shares	Nov. 30, 2022 USD ($)	Aug. 31, 2021 USD ($) $ / shares	Nov. 30, 2019 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 $ / shares	Jun. 30, 2016 $ / shares
Common Stock, Shares Authorized (in shares)											300,000,000	300,000,000
Common Stock, Shares, Issued (in shares)											98,935,025	74,519,103
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares											$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)											10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)											15,617	15,617
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares											$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											15,617	15,617
Common Stock, Shares, Outstanding (in shares)											98,935,025	74,519,103
Jefferies L L C [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares									$ 0.001
Conversion of Common Stock into Series E Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)				5,000,000
Conversion of Stock, Shares Issued (in shares)				5,000
Employee Director And Consultant Equity Incentive Plan2020 [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)					3,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	6,000,000	3,000,000	2,250,000		3,000,000
Securities Purchase Agreement [Member]
Preferred Stock, Shares Issued (in shares)							4,963
Partners' Capital Account, Units, Sold in Private Placement (in shares)							8,188,804
Shares Issued, Price Per Share (in dollars per share) | $ / shares														$ 2.015
Proceeds from Issuance of Private Placement | $							$ 16.5
Proceeds From Issuance Of Private Placement Net | $							$ 15.3
Sale of Stock, Number of Shares Issued in Transaction (in shares)							3,225,804
At the Market Offering [Member] | Jefferies L L C [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares											$ 0.84
Sale of Stock, Price Per Share (in dollars per share) | $ / shares													$ 3.46
Sale of Stock, Authorized Amount | $								$ 75	$ 50
Stock Issued During Period, Shares, New Issues (in shares)											24,300,000	2,100,000
Stock Issued During Period, Value, Issued for Services | $											$ 20.3	$ 7.2
Common Stock [Member]
Number Of Votes Per Share											1
Stock Issued During Period, Shares, New Issues (in shares)											24,261,000
Common Stock [Member] | Stock Exchange Shares from Existing Shareholders [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)						5,000,000
Common Stock [Member] | At the Market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)												2,069,000
Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)											0
Preferred Stock [Member] | Preferred Share Exchange [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)						5,000
Preferred Stock [Member] | At the Market Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)												0
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)											85	85
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											85	85
Series B Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)											4,026	4,026
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											4,026	4,026
Series C Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)											3,506	3,506
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											3,506	3,506
Series C Preferred Stock [Member] | Preferred Share Exchange [Member]
Sale of Stock, Price Per Share (in dollars per share) | $ / shares										$ 3.43
Debt Instrument, Convertible, Beneficial Conversion Feature | $										$ 2.8
Series C Preferred Stock [Member] | Private Placement [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)										0.001
Proceeds From Issuance Of Private Placement Net | $										$ 31
Sale of Stock, Number of Shares Issued in Transaction (in shares)										9,014,960
Sale of Stock, Price Per Share (in dollars per share) | $ / shares										$ 3.55
Sale of Stock, Consideration Received Per Transaction | $										$ 32
Stock Issued During Period, Shares, Conversion of Units (in shares)										1
Sale of Stock, Number of Warrants, Per Unit (in shares)										1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)										1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares										$ 7.1
Convertible Preferred Stock, Weighted Average Stock Price, Percent										3%
Series C Preferred Stock [Member] | Private Placement [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Year)										5 years
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)											3,000	3,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											3,000	3,000
Series E Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)											5,000	5,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)											5,000	5,000
Series A Through E [Member] | Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1,000
Convertible Preferred Stock, Common Stock Ownership Limit, Percent				9.99%
Convertible Preferred Stock, Beneficial Ownership Limitation, Percent				19.99%
Convertible Preferred Stock, Beneficial Ownership Limitation, Notice Period Before Increase (Year)				61 years

Note 10 - Net Loss Per Share (D

Note 10 - Net Loss Per Share (Details Textual) - shares shares in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	39.4	38.4

Note 11 - Stock and Employee _3

Note 11 - Stock and Employee Benefit Plans (Details Textual) - USD ($) $ / shares in Units, $ in Millions					12 Months Ended
	Jun. 20, 2023	Jun. 22, 2022	Jun. 25, 2021	Apr. 01, 2020	Dec. 31, 2023	Dec. 31, 2022	Jun. 23, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					3,727,942	3,075,282
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)					$ 0.85	$ 1.96
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)					9,284,808
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)					154,656	181,466
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount					$ 4.3
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 2 months 26 days
Share-Based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					750,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent					85%
Employee Director And Consultant Equity Incentive Plan2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	14,750,000		5,750,000				3,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	6,000,000	3,000,000	2,250,000	3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)						10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)					3,727,942

Note 11 - Stock and Employee _4

Note 11 - Stock and Employee Benefit Plans - Schedule of Share-based Payment Award, Stock Options (Details) - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Risk free interest rate, minimum	3.33%	1.43%
Risk free interest rate, maximum	4.11%	3.39%
Dividend yield	0%	0%
Expected volatility, minimum	79.50%	79.90%
Expected volatility, maximum	98.60%	81.10%
Minimum [Member]
Expected term (in years) (Year)	5 years 6 months	5 years 6 months
Maximum [Member]
Expected term (in years) (Year)	5 years 8 months 23 days	5 years 8 months 23 days

Note 11 - Stock and Employee _5

Note 11 - Stock and Employee Benefit Plans - Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Granted, balance (in shares)	3,727,942	3,075,282
Executive Officers and Management [Member]
Outstanding, balance (in shares)	300,000
Outstanding, exercise price (in dollars per share)	$ 4.65
Outstanding, balance (in shares)	300,000	300,000
Outstanding, exercise price (in dollars per share)	$ 4.65	$ 4.65
Outstanding, contractual life (Year)	5 years 8 months 1 day
Vested or expected to vest, balance (in shares)	300,000
Vested or expected to vest, exercise price (in dollars per share)	$ 4.65
Vested or expected to vest, contractual life (Year)	5 years 8 months 1 day
Exercisable, balance (in shares)	300,000
Exercisable, exercise price (in dollars per share)	$ 4.65
Exercisable, contractual life (Year)	5 years 8 months 1 day
Exercisable, intrinsic value	$ 0
Employee Director And Consultant Equity Incentive Plan2020 [Member]
Outstanding, balance (in shares)	13,430,366
Outstanding, exercise price (in dollars per share)	$ 3.21
Outstanding, intrinsic value	$ 0
Granted, balance (in shares)	3,727,942
Granted, exercise price (in dollars per share)	$ 1.22
Granted, intrinsic value	$ 0
Canceled, balance (in shares)	2,655,237
Canceled, exercise price (in dollars per share)	$ 2.65
Canceled, intrinsic value	$ 0
Outstanding, balance (in shares)	14,503,071	13,430,366
Outstanding, exercise price (in dollars per share)	$ 2.8	$ 3.21
Outstanding, contractual life (Year)	5 years 10 months 24 days
Outstanding, intrinsic value	$ 0	$ 0
Vested or expected to vest, balance (in shares)	14,503,071
Vested or expected to vest, exercise price (in dollars per share)	$ 2.8
Vested or expected to vest, contractual life (Year)	5 years 10 months 24 days
Vested or expected to vest, intrinsic value	$ 0
Exercisable, balance (in shares)	10,292,063
Exercisable, exercise price (in dollars per share)	$ 3.21
Exercisable, contractual life (Year)	4 years 9 months
Exercisable, intrinsic value	$ 0

Note 11 - Stock and Employee _6

Note 11 - Stock and Employee Benefit Plans - Schedule of Employee Service Share-based Compensation Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based payment arrangement expense	$ 3,349	$ 4,402
Research and Development Expense [Member]
Share-based payment arrangement expense	1,190	1,905
General and Administrative Expense [Member]
Share-based payment arrangement expense	$ 2,159	$ 2,497

Note 13 - Leases (Details Textu

Note 13 - Leases (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Feb. 29, 2020 ft²	Aug. 31, 2015 ft²
Operating Lease, Payments	$ 2.2	$ 2.4
Sublease Office Space [Member] | Boston Massachusetts [Member]
Area of Real Estate Property (Square Foot) | ft²				3,950
Office and Laboratory Space [Member] | Hallbergmoos Germany [Member]
Area of Real Estate Property (Square Foot) | ft²			105,000
Lessee, Operating Lease, Term of Contract (Year)			12 years 6 months
Termination Fee	9.7
Tenant Improvements	$ 11.5

Note 13 - Leases - Operating Le

Note 13 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Operating lease costs		$ 1,169	$ 1,356
Variable lease costs (1)	[1]	679	737
Total lease cost		$ 1,848	$ 2,093
[1]Variable lease costs include certain additional charges for operating costs, including insurance, maintenance, taxes, utilities, and other costs incurred, which are billed based on both usage and as a percentage of the Company’s share of total square footage.